May 30, 2022

US FDA approves Amneal’s application for biosimilar

By PBR Staff Writer

To be marketed under the proprietary name fylnetra, pegfilgrastim-pbbk was developed in collaboration with Kashiv Biosciences. Fylnetra is used for the treatment of neutropenia, a condition that occurs